{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Berberine", "Multiple myeloma", "SPR-LC-MS/MS approach", "Target identification", "UHRF1"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32213189", "DateCompleted": {"Year": "2020", "Month": "09", "Day": "29"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "03", "Day": "25"}], "Language": ["eng"], "ELocationID": ["33", "10.1186/s12915-020-00766-8"], "Journal": {"ISSN": "1741-7007", "JournalIssue": {"Volume": "18", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Mar", "Day": "25"}}, "Title": "BMC biology", "ISOAbbreviation": "BMC Biol"}, "ArticleTitle": "Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1.", "Pagination": {"StartPage": "33", "MedlinePgn": "33"}, "Abstract": {"AbstractText": ["Current therapies for multiple myeloma (MM) are associated with toxicity and resistance, highlighting the need for novel effective therapeutics. Berberine (BBR), a botanical alkaloid derived from several Berberis medicinal plants, has exhibited anti-tumor effects, including against multiple myeloma (MM); however, the molecular mechanism underlying the anti-MM effect has not been previously described. This study aimed to identify the target of berberine and related mechanisms involved in its therapeutic activity against MM.", "Here, we demonstrated that BBR treatment killed MM cells in vitro and prolonged the survival of mice bearing MM xenografts in vivo. A screening approach integrating surface plasmon resonance (SPR) with liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified UHRF1 (ubiquitin-like with PHD and RING Finger domains 1) as a potential target of BBR. Combining molecular docking and SPR analysis, we confirmed UHRF1 as a BBR-binding protein and discovered that BBR binds UHRF1 in the tandem tudor domain and plant homeodomain (TTD-PHD domain). BBR treatment induced UHRF1 degradation via the ubiquitin-dependent proteasome system and reactivated p16<sup>INK4A</sup> and p73 in MM cells. Overexpression of UHRF1 promoted the MM cell proliferation and rendered MM cells more resistant to BBR, while silencing of UHRF1 with siRNA attenuated BBR-induced cytotoxicity.", "In summary, our study has identified UHRF1 as a direct target of BBR and uncovered molecular mechanisms involved in the anti-MM activity of BBR. Targeting UHRF1 through BBR may be a novel therapeutic strategy against MM."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Medical College of Jinan University, 601 Western Huangpu Avenue, Guangzhou, 510632, China."}, {"Identifier": [], "Affiliation": "Institute of Chinese Integrative Medicine, Chinese Medicine College, Jinan University, Guangzhou, 510632, China."}], "LastName": "Gu", "ForeName": "Chunming", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Medical College of Jinan University, 601 Western Huangpu Avenue, Guangzhou, 510632, China."}, {"Identifier": [], "Affiliation": "Institute of Chinese Integrative Medicine, Chinese Medicine College, Jinan University, Guangzhou, 510632, China."}], "LastName": "Yin", "ForeName": "Zhao", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China."}, {"Identifier": [], "Affiliation": "International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, Guangzhou, 510632, China."}], "LastName": "Nie", "ForeName": "Hong", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Medical College of Jinan University, 601 Western Huangpu Avenue, Guangzhou, 510632, China."}], "LastName": "Liu", "ForeName": "Yanjun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Medical College of Jinan University, 601 Western Huangpu Avenue, Guangzhou, 510632, China."}], "LastName": "Yang", "ForeName": "Juhua", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Medical College of Jinan University, 601 Western Huangpu Avenue, Guangzhou, 510632, China."}], "LastName": "Huang", "ForeName": "Guiping", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China. sjping88@163.com."}], "LastName": "Shen", "ForeName": "Jianping", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Integrative Medicine, Chinese Medicine College, Jinan University, Guangzhou, 510632, China. tchenly@jnu.edu.cn."}], "LastName": "Chen", "ForeName": "Liguo", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Medical College of Jinan University, 601 Western Huangpu Avenue, Guangzhou, 510632, China. tfeijia@jnu.edu.cn."}, {"Identifier": [], "Affiliation": "Institute of Chinese Integrative Medicine, Chinese Medicine College, Jinan University, Guangzhou, 510632, China. tfeijia@jnu.edu.cn."}], "LastName": "Fei", "ForeName": "Jia", "Initials": "J"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "BMC Biol", "NlmUniqueID": "101190720", "ISSNLinking": "1741-7007"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anticarcinogenic Agents"}, {"RegistryNumber": "0I8Y3P32UF", "NameOfSubstance": "Berberine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Anticarcinogenic Agents"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Berberine"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred C57BL"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Multiple Myeloma"}], "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385(9983):2197\u20132208. doi: 10.1016/S0140-6736(14)60493-1.", "ArticleIdList": ["10.1016/S0140-6736(14)60493-1", "25540889"]}, {"Citation": "Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676\u2013681. doi: 10.1053/j.seminoncol.2016.11.004.", "ArticleIdList": ["10.1053/j.seminoncol.2016.11.004", "PMC5283695", "28061985"]}, {"Citation": "Shank BR, Brown VT, Schwartz RN. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment. J Oncol Pharm Pract. 2015;21(1):36\u201351. doi: 10.1177/1078155213514468.", "ArticleIdList": ["10.1177/1078155213514468", "24395544"]}, {"Citation": "Hideshima T, Anderson KC. Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies. Semin Hematol. 2012;49(3):223\u2013227. doi: 10.1053/j.seminhematol.2012.04.006.", "ArticleIdList": ["10.1053/j.seminhematol.2012.04.006", "PMC3383768", "22726545"]}, {"Citation": "Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23(11):1964\u20131979. doi: 10.1038/leu.2009.173.", "ArticleIdList": ["10.1038/leu.2009.173", "PMC4737506", "19741722"]}, {"Citation": "Lin CC, Lin SY, Chung JG, Lin JP, Chen GW, Kao ST. Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle. Anticancer Res. 2006;26(2a):1097\u20131104.", "ArticleIdList": ["16619512"]}, {"Citation": "Letasiov\u00e1 S, Jantov\u00e1 S, Cip\u00e1k L, M\u00fackov\u00e1 M. Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett. 2006;239(2):254\u2013262. doi: 10.1016/j.canlet.2005.08.024.", "ArticleIdList": ["10.1016/j.canlet.2005.08.024", "16229943"]}, {"Citation": "Wang J, Qi Q, Feng Z, Zhang X, Huang B, Chen A, Prestegarden L, Li X, Wang J. Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway. Oncotarget. 2016;7(41):66944\u201366958.", "ArticleIdList": ["PMC5341849", "27557493"]}, {"Citation": "Yang X, Huang N. Berberine induces selective apoptosis through the AMPK-mediated mitochondrial/caspase pathway in hepatocellular carcinoma. Mol Med Rep. 2013;8(2):505\u2013510. doi: 10.3892/mmr.2013.1506.", "ArticleIdList": ["10.3892/mmr.2013.1506", "23732865"]}, {"Citation": "Palmieri A, Scapoli L, Iapichino A, Mercolini L, Mandrone M, Poli F, Gianni AB, Baserga C, Martinelli M. Berberine and Tinospora cordifolia exert a potential anticancer effect on colon cancer cells by acting on specific pathways. Int J Immunopathol Pharmacol. 2019;33:2058738419855567. doi: 10.1177/2058738419855567.", "ArticleIdList": ["10.1177/2058738419855567", "PMC6822188", "31663444"]}, {"Citation": "Hu HY, Li KP, Wang XJ, Liu Y, Lu ZG, Dong RH, Guo HB, Zhang MX. Set9, NF-\u03baB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells. Acta Pharmacol Sin. 2013;34(1):157\u2013166. doi: 10.1038/aps.2012.161.", "ArticleIdList": ["10.1038/aps.2012.161", "PMC4086496", "23247593"]}, {"Citation": "Ruan H, Zhan YY, Hou J, Xu B, Chen B, Tian Y, Wu D, Zhao Y, Zhang Y, Chen X, et al. Berberine binds RXRalpha to suppress beta-catenin signaling in colon cancer cells. Oncogene. 2017;36(50):6906\u20136918. doi: 10.1038/onc.2017.296.", "ArticleIdList": ["10.1038/onc.2017.296", "PMC5735301", "28846104"]}, {"Citation": "Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 2008;68(13):5370\u20135379. doi: 10.1158/0008-5472.CAN-08-0511.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-0511", "18593939"]}, {"Citation": "Qing Y, Hu H, Liu Y, Feng T, Meng W, Jiang L, Sun Y, Yao Y. Berberine induces apoptosis in human multiple myeloma cell line U266 through hypomethylation of p53 promoter. Cell Biol Int. 2014;38(5):563\u2013570. doi: 10.1002/cbin.10206.", "ArticleIdList": ["10.1002/cbin.10206", "24843889"]}, {"Citation": "Luo X, Gu J, Zhu R, Feng M, Zhu X, Li Y, Fei J. Integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma cells in response to berberine. BMC Syst Biol. 2014;8:82. doi: 10.1186/1752-0509-8-82.", "ArticleIdList": ["10.1186/1752-0509-8-82", "PMC4096730", "25000828"]}, {"Citation": "Wang N, Wang X, Tan HY, Li S, Tsang CM, Tsao SW, Feng Y. Berberine suppresses cyclin D1 expression through proteasomal degradation in human hepatoma cells. Int J Mol Sci. 2016;17(11):1899.", "ArticleIdList": ["PMC5133898", "27854312"]}, {"Citation": "Tsui H, Zi M, Wang S, Chowdhury SK, Prehar S, Liang Q, Cartwright EJ, Lei M, Liu W, Wang X. Smad3 couples Pak1 with the antihypertrophic pathway through the E3 ubiquitin ligase, Fbxo32. Hypertension. 2015;66(6):1176\u20131183. doi: 10.1161/HYPERTENSIONAHA.115.06068.", "ArticleIdList": ["10.1161/HYPERTENSIONAHA.115.06068", "26483344"]}, {"Citation": "Wang L, Cao H, Lu N, Liu L, Wang B, Hu T, Israel DA, Peek RM, Jr, Polk DB, Yan F. Berberine inhibits proliferation and down-regulates epidermal growth factor receptor through activation of Cbl in colon tumor cells. PLoS One. 2013;8(2):e56666. doi: 10.1371/journal.pone.0056666.", "ArticleIdList": ["10.1371/journal.pone.0056666", "PMC3573001", "23457600"]}, {"Citation": "Bolduc OR, Pelletier JN, Masson JF. SPR biosensing in crude serum using ultralow fouling binary patterned peptide SAM. Anal Chem. 2010;82(9):3699\u20133706. doi: 10.1021/ac100035s.", "ArticleIdList": ["10.1021/ac100035s", "20353164"]}, {"Citation": "Dai X, Yan J, Fu X, Pan Q, Sun D, Xu Y, Wang J, Nie L, Tong L, Shen A, et al. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin Cancer Res. 2017;23(20):6267\u20136278. doi: 10.1158/1078-0432.CCR-17-0242.", "ArticleIdList": ["10.1158/1078-0432.CCR-17-0242", "28710312"]}, {"Citation": "Alhosin M, Omran Z, Zamzami MA, Al-Malki AL, Choudhry H, Mousli M, Bronner C. Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer. J Exp Clin Cancer Res. 2016;35(1):174. doi: 10.1186/s13046-016-0453-5.", "ArticleIdList": ["10.1186/s13046-016-0453-5", "PMC5108085", "27839516"]}, {"Citation": "Ma J, Peng J, Mo R, Ma S, Wang J, Zang L, Li W, Fan J. Ubiquitin E3 ligase UHRF1 regulates p53 ubiquitination and p53-dependent cell apoptosis in clear cell renal cell carcinoma. Biochem Biophys Res Commun. 2015;464(1):147\u2013153. doi: 10.1016/j.bbrc.2015.06.104.", "ArticleIdList": ["10.1016/j.bbrc.2015.06.104", "26102039"]}, {"Citation": "Guan D, Factor D, Liu Y, Wang Z, Kao HY. The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein. Oncogene. 2013;32(33):3819\u20133828. doi: 10.1038/onc.2012.406.", "ArticleIdList": ["10.1038/onc.2012.406", "PMC3578017", "22945642"]}, {"Citation": "Boukhari A, Alhosin M, Bronner C, Sagini K, Truchot C, Sick E, Schini-Kerth VB, Andr\u00e9 P, M\u00e9ly Y, Mousli M, et al. CD47 activation-induced UHRF1 over-expression is associated with silencing of tumor suppressor gene p16INK4A in glioblastoma cells. Anticancer Res. 2015;35(1):149\u2013157.", "ArticleIdList": ["25550546"]}, {"Citation": "Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26(12):2538\u20132545. doi: 10.1038/leu.2012.141.", "ArticleIdList": ["10.1038/leu.2012.141", "22648449"]}, {"Citation": "Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115\u2013130. doi: 10.1016/j.ccr.2007.07.004.", "ArticleIdList": ["10.1016/j.ccr.2007.07.004", "PMC2730509", "17692804"]}, {"Citation": "Fang J, Cheng J, Wang J, Zhang Q, Liu M, Gong R, Wang P, Zhang X, Feng Y, Lan W, et al. Hemi-methylated DNA opens a closed conformation of UHRF1 to facilitate its histone recognition. Nat Commun. 2016;7:11197. doi: 10.1038/ncomms11197.", "ArticleIdList": ["10.1038/ncomms11197", "PMC4822050", "27045799"]}, {"Citation": "Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208. doi: 10.1016/j.ctrv.2018.09.001.", "ArticleIdList": ["10.1016/j.ctrv.2018.09.001", "30245231"]}, {"Citation": "Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52.", "ArticleIdList": ["PMC4929712", "27363832"]}, {"Citation": "Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S. Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma. Mediators Inflamm. 2017;2017:1852517. doi: 10.1155/2017/1852517.", "ArticleIdList": ["10.1155/2017/1852517", "PMC5635476", "29089667"]}, {"Citation": "Zhao GL, Yu LM, Gao WL, Duan WX, Jiang B, Liu XD, Zhang B, Liu ZH, Zhai ME, Jin ZX, et al. Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress. Acta Pharmacol Sin. 2016;37(3):354\u2013367. doi: 10.1038/aps.2015.136.", "ArticleIdList": ["10.1038/aps.2015.136", "PMC4775848", "26806299"]}, {"Citation": "Fu L, Chen W, Guo W, Wang J, Tian Y, Shi D, Zhang X, Qiu H, Xiao X, Kang T, et al. Berberine targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and cytochrome-c/caspase signaling to suppress human cancer cell growth. PLoS One. 2013;8(7):e69240. doi: 10.1371/journal.pone.0069240.", "ArticleIdList": ["10.1371/journal.pone.0069240", "PMC3711861", "23869238"]}, {"Citation": "Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D, Huck J, Shi J, Gavin J, Brownell J, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018;24(2):186\u2013193. doi: 10.1038/nm.4474.", "ArticleIdList": ["10.1038/nm.4474", "29334375"]}, {"Citation": "Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777\u20133784. doi: 10.1182/blood-2005-03-1173.", "ArticleIdList": ["10.1182/blood-2005-03-1173", "PMC1895114", "16099887"]}, {"Citation": "Wang D, Ma L, Wang B, Liu J, Wei W. E3 ubiquitin ligases in cancer and implications for therapies. Cancer Metastasis Rev. 2017;36(4):683\u2013702. doi: 10.1007/s10555-017-9703-z.", "ArticleIdList": ["10.1007/s10555-017-9703-z", "29043469"]}, {"Citation": "Nicholson B, Marblestone JG, Butt TR, Mattern MR. Deubiquitinating enzymes as novel anticancer targets. Future Oncol. 2007;3(2):191\u2013199. doi: 10.2217/14796694.3.2.191.", "ArticleIdList": ["10.2217/14796694.3.2.191", "PMC2291548", "17381419"]}, {"Citation": "Sidhu H, Capalash N. UHRF1: the key regulator of epigenetics and molecular target for cancer therapeutics. Tumour Biol. 2017;39(2):1010428317692205. doi: 10.1177/1010428317692205.", "ArticleIdList": ["10.1177/1010428317692205", "28218043"]}, {"Citation": "Nishiyama A, Yamaguchi L, Sharif J, Johmura Y, Kawamura T, Nakanishi K, Shimamura S, Arita K, Kodama T, Ishikawa F, et al. Uhrf1-dependent H3K23 ubiquitylation couples maintenance DNA methylation and replication. Nature. 2013;502(7470):249\u2013253. doi: 10.1038/nature12488.", "ArticleIdList": ["10.1038/nature12488", "24013172"]}, {"Citation": "Kim JK, Kan G, Mao Y, Wu Z, Tan X, He H, Lee C. UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis. Mol Oncol. 2020;14(2):329\u201346.", "ArticleIdList": ["PMC6998393", "31782885"]}, {"Citation": "Yu C, Xing F, Tang Z, Bronner C, Lu X, Di J, Zeng S, Liu J. Anisomycin suppresses Jurkat T cell growth by the cell cycle-regulating proteins. Pharmacol Rep. 2013;65(2):435\u2013444. doi: 10.1016/S1734-1140(13)71019-3.", "ArticleIdList": ["10.1016/S1734-1140(13)71019-3", "23744428"]}, {"Citation": "Krifa M, Leloup L, Ghedira K, Mousli M, Chekir-Ghedira L. Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain, UHRF1, and DNMT1 expressions. Nutr Cancer. 2014;66(7):1220\u20131227. doi: 10.1080/01635581.2014.951729.", "ArticleIdList": ["10.1080/01635581.2014.951729", "25207720"]}, {"Citation": "Ibrahim A, Alhosin M, Papin C, Ouararhni K, Omran Z, Zamzami MA, Al-Malki AL, Choudhry H, Mely Y, Hamiche A, et al. Thymoquinone challenges UHRF1 to commit auto-ubiquitination: a key event for apoptosis induction in cancer cells. Oncotarget. 2018;9(47):28599\u201328611. doi: 10.18632/oncotarget.25583.", "ArticleIdList": ["10.18632/oncotarget.25583", "PMC6033341", "29983883"]}, {"Citation": "Xu C-P, Qi Y, Cui Z, Yang Y-J, Wang J, Hu Y-J, Yu B, Wang F-Z, Yang Q-P, Sun H-T. Discovery of novel elongator protein 2 inhibitors by compound library screening using surface plasmon resonance. RSC Adv. 2019;9(3):1696\u20131704. doi: 10.1039/C8RA09640F.", "ArticleIdList": ["10.1039/C8RA09640F", "PMC9059734", "35518050"]}, {"Citation": "Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020\u20132028. doi: 10.1182/blood-2005-11-013458.", "ArticleIdList": ["10.1182/blood-2005-11-013458", "PMC1895543", "16728703"]}]}], "History": [{"Year": "2019", "Month": "9", "Day": "16"}, {"Year": "2020", "Month": "3", "Day": "5"}, {"Year": "2020", "Month": "3", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "3", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "9", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "3", "Day": "25"}], "PublicationStatus": "epublish", "ArticleIdList": ["32213189", "PMC7098108", "10.1186/s12915-020-00766-8", "10.1186/s12915-020-00766-8"]}}]}